Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms PAISLEY
- Sponsors Bristol-Myers Squibb
- 15 Nov 2023 Results exploring whether patients could sustain CLASI-50 over time and achieve 100% reduction in CLASI activity were presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of transcriptomic analysis of patients treated with DEUC to further explore the mechanism of action (MOA) and effects of DEUC in SLE, presented at the ACR Convergence 2023
- 15 Nov 2023 Results of post hoc analysis assessing efficacy, time to response, and sustained responses over 48 Weeks of deucravacitinib comparing with placebo in systemic lupus erythematosus, presented at the ACR Convergence 2023.